<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03382457</url>
  </required_header>
  <id_info>
    <org_study_id>2017-19</org_study_id>
    <nct_id>NCT03382457</nct_id>
  </id_info>
  <brief_title>Edwards Cardioband Tricuspid Valve Reconstruction System Early Feasibility Study</brief_title>
  <official_title>Edwards Cardioband Tricuspid Valve Reconstruction System Early Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early feasibility study to assess the safety and performance of the Edwards Cardioband&#xD;
      Tricuspid Valve Reconstruction System&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a multi-center, prospective, single-arm, and non-randomized study designed to&#xD;
      evaluate the safety and performance of the Edwards Cardioband Tricuspid Valve Reconstruction&#xD;
      System&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">June 2028</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from device or procedure-related adverse events</measure>
    <time_frame>30 days</time_frame>
    <description>Safety assessed by freedom from device or procedure-related adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NYHA Functional Class</measure>
    <time_frame>30 days, 6 Months, 12 Months, annual for five years</time_frame>
    <description>Number of patients with improvement in NYHA class</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six minute walk test</measure>
    <time_frame>30 days, 6 Months, 12 Months</time_frame>
    <description>Increase in distance (m) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in TR grade</measure>
    <time_frame>30 days, 6 Months, 12 Months, annual for five years</time_frame>
    <description>Number of patients with reduction in TR from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Status</measure>
    <time_frame>30 days, 6 Months, 12 Months</time_frame>
    <description>Number of points of improvement in health status as measured by Kansas City Cardiomyopathy Questionnaire and 36 item short form survey (SF-36)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Tricuspid Regurgitation</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with the Edwards Cardioband Tricuspid Valve Reconstruction System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter Tricuspid Valve Reconstruction</intervention_name>
    <description>Reconstruction of the tricuspid valve through a transcatheter approach</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Edwards Cardioband Tricuspid Valve Reconstruction</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic functional tricuspid regurgitation (moderate or greater)&#xD;
&#xD;
          -  Symptomatic despite medical therapy&#xD;
&#xD;
          -  The local site Heart Team determines that the patient is appropriate for transcatheter&#xD;
             tricuspid reconstruction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unsuitable anatomy&#xD;
&#xD;
          -  Primary tricuspid valve disease&#xD;
&#xD;
          -  Previous tricuspid valve repair or replacement&#xD;
&#xD;
          -  Co-morbid condition(s) that, in the opinion of the investigator, could limit the&#xD;
             patient's ability to participate in the study, including compliance with follow-up&#xD;
             requirements, or that could impact the scientific integrity of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Gray, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lankenau Heart, Wynnewood, PA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center /New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lankenau Medical Center</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Hosiptal Baylor Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 19, 2017</study_first_submitted>
  <study_first_submitted_qc>December 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2017</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Functional</keyword>
  <keyword>TR</keyword>
  <keyword>FTR</keyword>
  <keyword>Transcatheter</keyword>
  <keyword>Reconstruction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

